Analysts Expect CTI BioPharma Corp. (CTIC) to Announce -$0.70 Earnings Per Share
Equities research analysts expect CTI BioPharma Corp. (NASDAQ:CTIC) to report ($0.70) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for CTI BioPharma Corp.’s earnings. CTI BioPharma Corp. also posted earnings of ($0.70) per share during the same quarter last year. The firm is scheduled to report its next earnings report on Thursday, August 3rd.
On average, analysts expect that CTI BioPharma Corp. will report full-year earnings of ($3.00) per share for the current financial year. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for CTI BioPharma Corp..
CTI BioPharma Corp. (NASDAQ:CTIC) last announced its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by $0.01. CTI BioPharma Corp. had a negative return on equity of 644.50% and a negative net margin of 346.56%. The firm had revenue of $0.75 million for the quarter.
Shares of CTI BioPharma Corp. (NASDAQ CTIC) traded up 2.42% during mid-day trading on Tuesday, hitting $3.39. The stock had a trading volume of 33,279 shares. The stock’s market capitalization is $95.07 million. The stock has a 50 day moving average of $3.75 and a 200-day moving average of $3.87. CTI BioPharma Corp. has a 52 week low of $2.70 and a 52 week high of $6.48.
Several institutional investors have recently bought and sold shares of the stock. Segantii Capital Management Ltd purchased a new position in CTI BioPharma Corp. during the first quarter valued at approximately $102,000. Acadian Asset Management LLC purchased a new position in CTI BioPharma Corp. during the first quarter valued at approximately $181,000. Finally, Nine Chapters Capital Management LLC increased its position in CTI BioPharma Corp. by 152.9% in the first quarter. Nine Chapters Capital Management LLC now owns 43,500 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 26,300 shares during the last quarter. 23.71% of the stock is currently owned by institutional investors.
CTI BioPharma Corp. Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CTI BioPharma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.